You just read:

Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at 2019 ASCO and EHA Annual Meetings

News provided by

Innovent Biologics, Inc.

Jun 17, 2019, 20:00 ET